Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
-
In this report the natural compound deguelin potently and do
2024-10-12
In this report, the natural compound deguelin potently and dose-dependently suppressed Aurora B kinase activity in vitro, indicating that this compound is an effective Aurora B inhibitor. The docking study indicated that deguelin was docked into the ATP-binding pocket of Aurora B and formed hydropho
-
br Funding This study was supported
2024-10-12
Funding This study was supported by Grant UM1-CA186690 (NCI-CTEP) and R01CA204173 (CJB). This project used the UPCI Cancer Pharmacokinetics and Pharmacodynamics Facility (CPPF) and was supported in part by award P30-CA47904 and R50CA211241. Introduction Despite the efficacy of platinum based
-
br Conclusions br Acknowledgements We would like to
2024-10-12
Conclusions Acknowledgements We would like to thank the members of the Bergmann lab for fruitful discussions in the course of this work. This work was supported by the National Institute of General Medical Sciences (NIGMS) under award number R35 GM118330. The content is solely the responsibili
-
We made a number of choices in the original
2024-10-12
We made a number of choices in the original design of our experiments. First, we used only portions of the 5′ and 3′ regulatory elements from S. cerevisiae. The sequences of these regions were known [32] and our goal was to express the Pf-DHFR at low levels. In fact, our choice of only 600 bp of the
-
The primary structure of the A peptide can be divided
2024-10-11
The primary structure of the Aβ peptide can be divided into four regions based on hydrophobicity. The N-terminal residues 1–16 comprise the first hydrophilic region, which also contains the metal binding site. More specifically, side chain carboxylate of D1 and the side chain nitrogens of H6, H13 an
-
br Conclusion P gingivalis expresses various exopeptidases i
2024-10-11
Conclusion P. gingivalis expresses various exopeptidases, i.e., DPP4, DPP5, DPP7, DPP11, PtpA, and AOP, in periplasmic space, which produce di- and tri-peptides from most oligopeptides. This oligopeptide processing step is important as an extracellular event in the NHS Biotin of asaccharolytic P.
-
agonists simulate norepinephrine NE in binding to presynapti
2024-10-11
α2 agonists simulate norepinephrine (NE) in binding to presynaptic surface autoreceptors, which in turn mediates feedback inhibition of NE release. Another major control mechanism for noradrenergic neurotransmission is termination of signaling by presynaptic NE transporter (NET)-mediated NE reuptake
-
br Conclusions Triptans are HT B D F
2024-10-11
Conclusions Triptans are 5-HT1B/1D/(1F) receptors agonists and are considered as the gold standard for acute migraine treatment that have been proven effective. Unfortunately, they are contraindicated in patients with cardiovascular diseases due to their vasoconstrictor (side) effects (MaassenVan
-
Mouse iPSC Chemical Reprogramming Cocktails Kit plus br Pati
2024-10-11
Patients and methods The severity of disease documented at each outpatient visit was graded according to the modified Osserman classification: grade I, focal disease (e.g. restricted to ocular muscles); grade II, generalised disease that is mild (IIa) or moderate (IIb); grade III, severe generali
-
DIDS synthesis Several tertiary prevention studies are
2024-10-11
Several tertiary prevention studies are currently underway examining the use of dutasteride for prostate cancer treatment: (1) during expectant management of prostate cancer, (2) after radical prostatectomy in men at high risk for relapse, and (3) in men with metastatic disease. The Reduction by Dut
-
The gene SRD A encodes
2024-10-11
The gene SRD5A2 encodes the 5-α-reductase enzyme, which converts testosterone into dihydrotestosterone. Although dihydrotestosterone levels are considerably lower than testosterone, dihydrotestosterone has a five-fold stronger binding capacity to the androgen receptor and, thereby, a considerably mo
-
Signaling through Axl can lead to activation of
2024-10-11
Signaling through Axl can lead to activation of the PI3K/Akt and Ras/MAPK pathways which promote cellular phenotypes (e.g., transformation, migration) consistent with pro-survival and pro-metastatic effects., , Inhibition of Axl activity by a variety of approaches (including pharmacologic, dominant
-
Finally not only can ERs pair
2024-10-10
Finally, not only can ERs pair with different mGluRs in different transcription factor regions, but it is becoming increasingly clear that the same mGluRs can pair with distinct downstream signaling partners to have differential effects both within and across brain regions (Gross et al., 2016; Mann
-
Thus phosphorylation of p was used to measure the intracellu
2024-10-10
Thus, phosphorylation of p38 was used to measure the intracellular potency of ASK1 inhibitors. In this assay, HEK293/AP-1luc Fmoc-Leu-OH expressing human full-length ASK1 were incubated with compound for 18 h and then lysed and the level of phospho-p38 was quantified using the HTRF assay [33]. Re
-
br Acknowledgements This work is sponsored by the National
2024-10-10
Acknowledgements This work is sponsored by the National Natural Science Foundation of China (grant no. 31201963) and Youth Backbone Teachers Project in Henan Province Department of Education, China (grant no. 2016GGJS-061). Introduction Acute lymphoblastic leukemia (ALL) is a malignant disord
15511 records 41/1035 page Previous Next First page 上5页 4142434445 下5页 Last page